SeqOne – Weekly Recap

SeqOne continued to sharpen its positioning in clinical genomics this week, combining major product updates with an active conference and thought-leadership agenda. The company is rolling out a Spring 2026 release of its CE-IVD-certified platform, adding 72 features and extending its DiagAI engine to structural and copy number variants.

The release introduces UP²-SV, a pathogenicity model trained on more than 65,000 ClinVar structural variants, which reported 97.6% pathogenic recall in a clinical cohort. SeqOne also rebuilt its interpretation environment with tools such as cytoband navigation and BAF plots to unify views across SNVs and SVs for improved clinical usability.

Operationally, the platform is now deployed in more than 200 laboratories across over 30 countries, processing hundreds of thousands of genomic analyses annually. Case studies with hospitals in Split, Alicante, and Lisbon highlight end-to-end workflows across exome, oncology, and infectious disease, underscoring deeper integration in routine care.

On the commercial front, SeqOne is targeting visibility at the ESHG 2026 conference in Gothenburg, where Booth 610 will showcase DiagAI, GermVar for Oxford Nanopore–optimized whole genome analysis, and GenomeAlert! for variant reevaluation. This presence is aimed at hospital, lab, and precision-medicine customers as the firm seeks to expand its sales pipeline.

The company is also emphasizing AI governance and regulatory readiness through a June 4 webinar on rare disease diagnostics, co-hosted with naaia.ai. Topics will include explainability, transparency, and EU AI Act compliance, signaling a push to align its products with tightening European rules for clinical AI tools.

SeqOne’s VP of Product Innovation is slated to speak at the Santorini precision medicine conference on democratizing pharmacogenomics by linking NGS, AI, and clinical workflows. The focus on making complex genomic data interpretable at scale suggests an effort to embed pharmacogenomics into everyday practice and broaden recurring-use cases.

To support its growth, SeqOne is recruiting a remote Product Specialist in oncology and hematology, with a mandate to translate major oncology guidelines into product features. Overall, the week’s developments point to a stronger technology stack, expanding hospital footprint, and rising visibility in AI-driven clinical genomics, though financial metrics remain undisclosed.